Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient's sera of colorectal cancer

Clinica Chimica Acta

Volumn 412, Issue 15-16, 2011, Pages 1417-1422

  Chen, Jinn Shiun ^a,b   Kuo, Yung Bin ^c,d   Chou, Yeh Pin ^a   Chan, Chung Chuan ^a   Fan, Chung Wei ^e   Chen, Kuei Tien ^a   Huang, Ya Shu ^c   Chan, Err Cheng ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Autoantibody; Biomarker; Colorectal cancer; RPH3AL

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN ANTIBODY; RABPHILIN 3A LIKE PROTEIN AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RAB GTP-BINDING PROTEINS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79956325223     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.04.020     Document Type: Article

References (47)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Yabroff K.R., Mariotto A.B., Feuer E., Brown M.L. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ 2008, 17:947-959.
3. Walsh J.M., Terdiman J.P. Colorectal cancer screening: scientific review. JAMA 2003, 289:1288-1296.
4. Gellad Z.F., Provenzale D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology 2010, 138:2177-2190.
5. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003, 124:544-560.
6. Von Kleist S., Hesse Y., Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996, 16:2325-2331.
7. Carpelan-Holmstrom M., Louhimo J., Stenman U.H., Alfthan H., Jarvinen H., Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004, 66:296-302.
8. Blake K.E., Dalbow M.H., Concannon J.P., et al. Clinical significance of the preoperative plasma carcinoembryonic antigen (CEA) level in patients with carcinoma of the large bowel. Dis Colon Rectum 1982, 25:24-32.
9. Reipert B.M., Tanneberger S., Pannetta A., et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?. Cancer Immunol Immunother 2005, 54:1038-1042.
10. Hyodo I., Doi T., Endo H., et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998, 34:2041-2045.
11. Renehan A.G., Painter J.E., O'Halloran D., et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000, 85:3402-3408.
12. Hundt S., Haug U., Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007, 16:1935-1953.
13. Thomson D.M., Krupey J., Freedman S.O., Gold P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A 1969, 64:161-167.
14. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
15. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108:1411-1415.
16. Finn O.J. Immune response as a biomarker for cancer detection and a lot more. N Engl Med 2005, 353:1288-1290.
17. Imai H., Nakano Y., Kiyosawa K., Tan E.M. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993, 71:26-35.
18. Chen J.S., Chou Y.P., Chen K.T., et al. Detection of annexin A autoantibodies in sera from colorectal cancer patients. J Clin Gastroenterol 2011, 45:125-132.
19. Mosolits S., Harmenberg U., Ruden U., et al. Autoantibodies against the tumor-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 1999, 47:315-320.
20. Mosolits S., Steinitz M., Harmenberg U., et al. Immunogenic regions of the GA733-2 tumor-associated antigen recognised by autoantibodies of patients with colorectal carcinoma. Cancer Immunol Immunother 2002, 51:209-218.
21. Suppiah A., Alabi A., Madden L., Hartley J.E., Monson J.R., Greenman J. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis 2008, 23:595-600.
22. Kocer B., McKolanis J., Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol 2006, 6:4.
23. Ward R.L., Hawkins N.J., Coomber D., Disis M.L. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999, 60:510-515.
24. Kotake K., Ozaki N., Mizuta M., Sekiya S., Inagaki N., Seino S. Noc2, a putative zinc finger protein involved in exocytosis in endocrine cells. J Biol Chem 1997, 272:29407-29410.
25. Cheviet S., Coppola T., Haynes L.P., Burgoyne R.D., Regazzi R. The Rab-binding protein Noc2 is associated with insulin-containing secretory granules and is essential for pancreatic beta-cell exocytosis. Mol Endocrinol 2004, 18:117-126.
26. Katkoori V.R., Jia X., Chatla C., et al. Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphilin-3A-like gene in colorectal adenocarcinoma. Front Biosci 2008, 13:1050-1061.
27. Goi T., Takeuchi K., Katayama K., Hirose K., Yamaguchi A. Mutations of rabphillin-3A-like gene in colorectal cancers. Oncol Rep 2002, 9:1189-1192.
28. Han C.-L., Chen J.-S., Chan E.-C., et al. An informatics-assisted label free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics 2011, 10. 10.1074/mcp. M110.003087.
29. Chen J.-S., Chen K.-T., Fan C.-W., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
30. Geppert M., Bolshakov V.Y., Siegelbaum S.A., et al. The role of Rab3A in neurotransmitter release. Nature 1994, 369:493-497.
31. Oishi H., Sasaki T., Nagano F., et al. Localization of the Rab3 small G protein regulators in nerve terminals and their involvement in Ca2+-dependent exocytosis. J Biol Chem 1998, 273:34580-34585.
32. Zinkernagel R.M. What is missing in immunology to understand immunity?. Nat Immunol 2000, 1:181-185.
33. Houghton A.N., Gold J.S., Blachere N.E. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001, 13:134-140.
34. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
35. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52:4168-4174.
36. Yagihashi A., Asanuma K., Kobayashi D., et al. Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung cancer 2005, 48:217-221.
37. Pedrazzini L., Baroli A., Lomuscio G., Marzoli L. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study. Minerva Endocrinol 2009, 34:195-203.
38. Atalay C., Atalay G., Yilmaz K.B., Altinok M. The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma 2005, 52:32-35.
39. Nelson D.S. Autoantibodies in cancer patients. Pathology 1977, 9:155-160.
40. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340.
41. Fernandez Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005, 230:187-198.
42. Holten-Andersen M.N., Christensen I.J., Nielsen H.J., et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002, 8:156-164.
43. Ran Y., Hu H., Zhou Z., et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 2008, 14:2696-2700.
44. Liu W., Wang P., Li Z., et al. Evaluation of tumor-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol 2009, 69:57-63.
45. Chen Y., Lin P., Qiu S., et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 2007, 30:1137-1144.
46. Tang R., Ko M.C., Wang J.Y., et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 2001, 94:859-863.
47. Muller M., Meyer M., Schilling T., et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol 2006, 29:973-980.